Literature DB >> 2581966

Doxorubicin induces calcium release from terminal cisternae of skeletal muscle. A study on isolated sarcoplasmic reticulum and chemically skinned fibers.

F Zorzato, G Salviati, T Facchinetti, P Volpe.   

Abstract

In this study, we investigated the effect of the anticancer drug doxorubicin on Ca2+ fluxes of isolated highly purified sarcoplasmic reticulum fractions (longitudinal tubules and terminal cisternae (Saito, A., Seiler, S., Chu, A., and Fleischer, S. (1984) J. Cell Biol. 99, 875-885] and of chemically skinned skeletal muscle fibers of the rabbit. In terminal cisternae, doxorubicin inhibits Ca2+ uptake (IC50 at 0.5 microM) and increases 2.6-fold Ca2+-dependent ATPase rate (half-maximal activation at 3 microM) and unidirectional Ca2+ efflux (8-fold stimulation at 25 microM). On the contrary, doxorubicin is without effect on longitudinal tubules. In skinned muscle fibers, doxorubicin induces rapid and transient Ca2+ release, as measured by tension development (half-maximal stimulation at 6 microM), which is completely and reversibly inhibited by ruthenium red, a known inhibitor of Ca2+ release from isolated terminal cisternae. Doxorubicin has no effect on the sarcoplasmic reticulum Ca2+ pump and on the contractile apparatus of skinned muscle fibers. It is concluded that doxorubicin activates Ca2+ release from sarcoplasmic reticulum and opens a Ca2+ efflux pathway (Ca2+ channel) selectively localized in terminal cisternae. Doxorubicin might interact with Ca2+ channels involved in physiological Ca2+ release.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2581966

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Ion conduction and discrimination in the sarcoplasmic reticulum ryanodine receptor/calcium-release channel.

Authors:  A J Williams
Journal:  J Muscle Res Cell Motil       Date:  1992-02       Impact factor: 2.698

2.  Phenol increases intracellular [Ca2+] during twitch contractions in intact Xenopus skeletal myofibers.

Authors:  Leonardo Nogueira; Michael C Hogan
Journal:  J Appl Physiol (1985)       Date:  2010-08-19

Review 3.  Kinetic analysis of excitation-contraction coupling.

Authors:  N Ikemoto; M Ronjat; L G Mészáros
Journal:  J Bioenerg Biomembr       Date:  1989-04       Impact factor: 2.945

4.  Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart.

Authors:  R Zucchi; G Yu; S Ghelardoni; F Ronca; S Ronca-Testoni
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

5.  Antibodies to junctional sarcoplasmic reticulum proteins: probes for the Ca2+-release channel.

Authors:  F Zorzato; A Chu; P Volpe
Journal:  Biochem J       Date:  1989-08-01       Impact factor: 3.857

6.  D-myo-inositol 1,4,5-trisphosphate phosphatase in skeletal muscle.

Authors:  D Milani; P Volpe; T Pozzan
Journal:  Biochem J       Date:  1988-09-01       Impact factor: 3.857

7.  Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle.

Authors:  Laura A A Gilliam; Leonardo F Ferreira; Joseph D Bruton; Jennifer S Moylan; Håkan Westerblad; Daret K St Clair; Michael B Reid
Journal:  J Appl Physiol (1985)       Date:  2009-09-24

Review 8.  Critical sulfhydryls regulate calcium release from sarcoplasmic reticulum.

Authors:  J J Abramson; G Salama
Journal:  J Bioenerg Biomembr       Date:  1989-04       Impact factor: 2.945

9.  Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo.

Authors:  Shao-hui Zhang; Wen-quan Wang; Jia-ling Wang
Journal:  Acta Pharmacol Sin       Date:  2009-11       Impact factor: 6.150

10.  Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model.

Authors:  D A Dodd; J B Atkinson; R D Olson; S Buck; B J Cusack; S Fleischer; R J Boucek
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.